Eltroxin users sue drug, health funds

14 patients whose drug for treating hypothyroidism was reformulated without their knowledge file class-action suit.

By
September 24, 2012 00:54
ELTROXIN

ELTROXIN 370. (photo credit: Courtesy)

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

A lawyer representing 14 patients whose drug for treating hypothyroidism was reformulated without their knowledge have filed a class-action suit request to the Central Region District Court.

The lawsuit is aimed against Perrigo and GlaxoSmithKline Israel, and two health funds – Clalit and Maccabi Health Services.

Be the first to know - Join our Facebook page.


The lawyer has asked for NIS 4.5 billion in damages for his clients.

The Health Ministry did not initially require the companies to tell doctors about the change in the widely taken drug, yet these patients who take the drug for their chronic condition claim to have suffered serious side effects.

The ministry set up a committee to investigate the incident, but the lawyer and his clients were not satisfied.

The lawyer claimed that the health funds did not report problems with the drug, Eltroxin, “even though they knew about them,” and that the ministry “glossed over the health insurers’ obligations to update their doctors.”

The hypothyroid patients were exposed to the new formulation for seven months before they realized the drug was different, the attorney said.

JPOST VIDEOS THAT MIGHT INTEREST YOU:

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

Lab
August 31, 2014
Weizmann scientists bring nature back to artificially selected lab mice

By JUDY SIEGEL-ITZKOVICH